Last edition
News about "Phase 3 REDUCE-2 study"
Sobi Reports Positive Phase 3 Results for Pozdeutinurad in Gout
Sobi reports positive Phase 3 REDUCE-2 results for investigational gout treatment pozdeutinurad, demonstrating sustained serum urate reduction over 12 months.
Phase 3 REDUCE-2 Study | 30/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members